Tirzepatide
Refilling Soon
This peptide is currently out of stock. Get notified the moment it's available.
About Tirzepatide
Tirzepatide is a first-in-class dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 receptor agonist — a single molecule simultaneously engaging two complementary incretin receptors implicated in metabolic regulation. Approved as Mounjaro for type 2 diabetes and Zepbound for obesity, tirzepatide's clinical trial data (SURMOUNT programme) demonstrated body weight reductions of up to 22.5% — the largest weight reduction reported for any pharmacological intervention in clinical trials to date. Its dual mechanism offers distinct advantages over single GLP-1 agonists: GIP receptor activation complements GLP-1's insulin secretion and appetite suppression with improvements in insulin sensitivity, adipocyte lipid metabolism, and a favourable tolerability profile. Research interest spans obesity and metabolic syndrome mechanisms, type 2 diabetes pathophysiology, cardiovascular risk reduction (ongoing SURPASS-CVOT programme), non-alcoholic fatty liver disease, and the comparative pharmacodynamics of incretin receptor polypharmacology. The interaction between GIP and GLP-1 receptor co-agonism represents an exciting frontier in metabolic biology with implications beyond what single-agonist studies can reveal. Supplied at ≥99% HPLC purity.
Usage Guidelines
✓ Suitable For
- Premier dual-agonist compound essential for incretin polypharmacology and metabolic research
- Ideal for obesity mechanism research — largest clinical weight reduction data of any drug class
- Suitable for type 2 diabetes NASH and cardiovascular metabolic risk research programmes
- Valuable for comparative studies against GLP-1 single agonists to isolate GIP receptor contributions
✗ Not Recommended For
- Not for use without medical supervision — GIP/GLP-1 agonists require careful dose titration
- Not suitable for individuals with personal or family history of medullary thyroid carcinoma
- GI side effects are common during initiation — monitor research subjects carefully
- Consult an endocrinologist or metabolic specialist before beginning any tirzepatide research protocol